Company profile
Arno Therapeutics, Inc.
OTC: ARNI · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 32
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$11.5M
Employees
4
as of 2026-08-30
Market cap
$4.9k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02015
Net income-$11.5M-$11.5M2015
Operating income-$13.4M-$13.4M2015
Total assets$361.2k$361.2k2015
Liabilities$9.0M$9.0M2015
Equity-$8.6M-$8.6M2015
Revenue trend
FY2008 – FY2015 · USD
FY08
FY09
FY10
FY11
FY12
FY13
FY14
FY15
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Arno Therapeutics, Inc.’s revenue?
Arno Therapeutics, Inc. booked $0 in FY2015 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
PAO Group, Inc.——NovAccess Global Inc.——LadRx Corporation——Life Stem Genetics Inc.——Innovation1 Biotech Inc.——Xeno Transplants Corporation——Key facts
CEODavid M. Tanen
SectorHealthcare
IndustryBiotechnology
HeadquartersFlemington, NJ
ExchangeOTC: ARNI
Employees4
IPO date2008-06-11
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.